BioSpace News Archive

Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth “Conversations” video podcast, a review and interactive discussion of Cognition’s CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer’s & Parkinson’s Diseases Conference.

CohBar, Inc. and Morphogenesis, Inc. today announced that they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.

Wave Life Sciences Ltd. today announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9-ALS/FTD).

Monte Rosa Therapeutics, Inc. today announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1.

Genprex, Inc. today released a new video where the company’s Chief Medical Officer, Mark Berger, MD, discusses the recently presented positive preclinical data for the NPRL2 gene by Genprex’s research collaborators.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH).

ImmPACT Bio USA, Inc. today announced that it will participate at the 2023 Jefferies Healthcare Conference, to be held from June 7-9, 2023, in New York.

Life Biosciences announced the appointment of Ming Yang, Ph.D., as Senior Vice President of Research and Development.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel.

T2 Biosystems, Inc. today announced it has initiated a process to explore a range of strategic alternatives focused on maximizing value.